The Kogi Ministry of Health’s Neglected Tropical Disease Programme, in collaboration with Sightsavers, has inaugurated the 2025 Mass Administration of Medicines for Onchocerciasis (River Blindness) ...

Public health campaigns had made significant strides toward eradicating diseases like elephantitis and river blindness. But this progress has since unraveled with the second Trump administration.

Under the agreement, which marks Mayo Clinic's first strategic collaboration of this scale with a global biopharmaceutical company, Merck will leverage Mayo Clinic's extensive multimodal ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

German Merck has set up a new collaboration with U.K. medtech company Calla Lily Clinical Care to work on its next-generation intravaginal drug delivery approach. London-based Calla Lily is working on ...

Merck is rated Buy after extending Keytruda's patent protection to late-2029, delaying the anticipated patent cliff, and unlocking significant near-term value. The extended exclusivity creates a ...

For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.

Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, and Mayo Clinic, the world's top-ranked hospital system, today announced a research and development agreement to apply artificial ...

New KEYTRUDA indications are expected to preserve Merck's top line, significantly aided by the high single-digit Animal Health/Livestock and the triple-digit Winrevair revenue growth in FY2025.

Merck, known as MSD outside of the US and Canada, and Mayo Clinic, the world's top-ranked hospital system, announced a research and development agreement to apply artificial intelligence (AI), ...